论文信息 - Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens - 字舞流文

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

P. Ang | K. Rau | M. Hou | T. Yau | N. Masuda | Y. Yap | H. Chung | Shang-Wen Chen | A. Kwong | L. Tseng | R. Ngan | Yen-Shen Lu | K. Lee | M. Dai | T. Sangai | Yin-Hsun Feng | T. Ng | J. Bebchuk | S. Ow | R. Bryce | V. Kok | Sung‐Chao Chu | Sung Bae Kim | Shou-Tung Chen | Johnson Lin | Mei Chieh Chen